Pfizer lung cancer pill rejected by NICE

LONDON (Reuters) – Pfizer's new lung cancer pill Xalkori is too expensive to be worth using on Britain's state health service, the country's health cost watchdog said on Wednesday. The National Institute for Health and Clinical Excellence (NICE) said the drug, which works by blocking enzymes that can stimulate tumour growth, could not be considered a cost-effective use of National Health Service resources. The agency's draft guidance on the drug – which costs 4,689 pounds for a 30-day supply – is now open for consultation. …